Grufity logo
Grufity logo

Latest Kynam Capital Management, LP Stock Portfolio

$1.81Billion | No. of Holdings #32

Kynam Capital Management, LP Performance

2026 Q2+13.83%
YTD+17.44%
2025+37.48%

About Kynam Capital Management, LP and 13F Hedge Fund Stock Holdings

On 2026-08-14, the fund reported it's updated stock portfolio. In the 13F Holdings report, Kynam Capital Management, LP reported an equity portfolio of $1.8 Billions as of 30 Jun, 2026. <br><br> The top stock holdings of Kynam Capital Management, LP are CLDX, SNDX, PCVX. The fund has invested 10.9% of it's portfolio in CELLDEX THERAPEUTICS INC NEW and 9.7% of portfolio in SYNDAX PHARMACEUTICALS INC. <br><br> The fund managers got completely rid off KALVISTA PHARMACEUTICALS INC (KALV), APELLIS PHARMACEUTICALS INC (APLS) and SOLENO THERAPEUTICS INC (SLNO) stocks. They significantly reduced their stock positions in BIOCRYST PHARMACEUTICALS INC (BCRX), CANDEL THERAPEUTICS INC (CADL) and BEAM THERAPEUTICS INC (BEAM). Kynam Capital Management, LP opened new stock positions in SUMMIT THERAPEUTICS INC (SMMT), INSMED INC (INSM) and PARABILIS MEDICINES INC. The fund showed a lot of confidence in some stocks as they added substantially to VIRIDIAN THERAPEUTICS INC (VRDN), RELAY THERAPEUTICS INC (RLAY) and ALECTOR INC (ALEC).
Kynam Capital Management, LP Equity Portfolio Value
Last Reported on: 14 Aug, 2026
$1.81Billion
  as of Aug 14, 2026

Kynam Capital Management, LP Annual Return Estimates Vs S&P 500

Our best estimate is that Kynam Capital Management, LP made a return of 13.83% in the last quarter. In trailing 12 months, it's portfolio return was 110.63%.
  • Performance
  • S&P 500

New Buys

Ticker$ Bought
summit therapeutics inc17,484,000
insmed inc10,662,000
parabilis medicines inc6,842,500
engene therapeutics inc792,089
traws pharma inc71,175
New stocks bought by Kynam Capital Management, LP

Additions

Ticker% Inc.
viridian therapeutics inc175
relay therapeutics inc131
alector inc90.42
legend biotech corp90.4
immunocore hldgs plc55.38
prelude therapeutics inc51.65
cytomx therapeutics inc.44.56
travere therapeutics inc27.47
Additions to existing portfolio by Kynam Capital Management, LP

Reductions

Ticker% Reduced
biocryst pharmaceuticals inc-55.59
candel therapeutics inc-51.63
beam therapeutics inc-22.85
vera therapeutics inc-14.95
cogent biosciences inc-9.17
celldex therapeutics inc new-8.86
Kynam Capital Management, LP reduced stake in above stock

Sold off

Ticker$ Sold
kalvista pharmaceuticals inc-36,655,800
engene holdings inc-9,240,100
climb bio inc-6,872,890
wave life sciences ltd-6,997,650
apellis pharmaceuticals inc-33,189,800
design therapeutics inc-8,348,210
biohaven ltd-5,946,400
evommune inc-14,380,200
Kynam Capital Management, LP got rid off the above stocks

Sector Distribution

Kynam Capital Management, LP has about 87.5% of it's holdings in Healthcare sector.

  • Healthcare
  • Others
Sector%
Healthcare87.5
Others12.5

Market Cap. Distribution

Kynam Capital Management, LP has about 1.6% of it's portfolio invested in the large-cap and mega-cap stocks.

  • MID-CAP
  • SMALL-CAP
  • UNALLOCATED
  • LARGE-CAP
Category%
MID-CAP60.1
SMALL-CAP25.2
UNALLOCATED12.5
LARGE-CAP1.6

Stocks belong to which Index?

About 82.5% of the stocks held by Kynam Capital Management, LP either belong to S&P 500 or RUSSELL 2000 index.

  • RUSSELL 2000
  • Others
Index%
RUSSELL 200082.5
Others17.5
Top 5 Winners (%)%
URGN
urogen pharma ltd
96.8 %
mbx biosciences inc
84.9 %
CADL
candel therapeutics inc
81.8 %
TVTX
travere therapeutics inc
74.1 %
NRIX
nurix therapeutics inc
56.5 %
Top 5 Winners ($)$
TVTX
travere therapeutics inc
48.4 M
URGN
urogen pharma ltd
44.1 M
BEAM
beam therapeutics inc
34.2 M
CLDX
celldex therapeutics inc new
30.6 M
LEGN
legend biotech corp
24.7 M
Top 5 Losers (%)%
BNR
burning rock biotech ltd
-47.2 %
CTMX
cytomx therapeutics inc.
-17.6 %
GERN
geron corp
-14.1 %
CRBU
caribou biosciences inc
-7.4 %
SNDX
syndax pharmaceuticals inc
-6.4 %
Top 5 Losers ($)$
CTMX
cytomx therapeutics inc.
-17.4 M
SNDX
syndax pharmaceuticals inc
-12.1 M
BNR
burning rock biotech ltd
-9.4 M
VRDN
viridian therapeutics inc
-5.2 M
GERN
geron corp
-1.4 M

Kynam Capital Management, LP Holdings Map

This heatmap illustrates the top 50 positions within the fund's portfolio.

Current Stock Holdings of Kynam Capital Management, LP

Kynam Capital Management, LP has 32 stocks in it's portfolio. About 72.7% of the portfolio is in top 10 stocks. CTMX proved to be the most loss making stock for the portfolio. TVTX was the most profitable stock for Kynam Capital Management, LP last quarter.

$1.81BTotal Value
41.00Positions
14 Aug, 2026Last Reported
Current holdings of Current Stock Holdings of Kynam Capital Management, LP, last reported on 14 Aug, 2026. Select a row with a linked ticker to view its historical trend.
ExpandHoldingsorted ascending% PortfolioShares Held$ Value% Change
BNR
Burning Rock Biotech Ltd

Burning Rock Biotech Ltd

BNR
Kynam Capital Management, LP's holding in Burning Rock Biotech Ltd over time
0.58%1,238,560
$10.52M
0.58%
increased 0.9 percentadded
IMCR
Immunocore Hldgs Plc

Immunocore Hldgs Plc

IMCR
Kynam Capital Management, LP's holding in Immunocore Hldgs Plc over time
2.41%1,375,000
$43.66M
2.41%
increased 55.38 percentadded
LEGN
Legend Biotech Corp

Legend Biotech Corp

LEGN
Kynam Capital Management, LP's holding in Legend Biotech Corp over time
4.79%3,001,200
$86.67M
4.79%
increased 90.4 percentadded